Ibuprofen for acute postoperative pain in children
Sara Pessano,Natasha R Gloeck,Luca Tancredi,Martin Ringsten,Ameer Hohlfeld,Sumayyah Ebrahim,Martina Albertella,Tamara Kredo,Matteo Bruschettini
DOI: https://doi.org/10.1002/14651858.cd015432.pub2
IF: 8.4
2024-01-07
Cochrane Database of Systematic Reviews
Abstract:Children often require pain management following surgery to avoid suffering. Effective pain management has consequences for healing time and quality of life. Ibuprofen, a frequently used non‐steroidal anti‐inflammatory drug (NSAID) administered to children, is used to treat pain and inflammation in the postoperative period. 1) To assess the efficacy and safety of ibuprofen (any dose) for acute postoperative pain management in children compared with placebo or other active comparators. 2) To compare ibuprofen administered at different doses, routes (e.g. oral, intravenous, etc.), or strategies (e.g. as needed versus as scheduled). We used standard Cochrane search methods. We searched CENTRAL, MEDLINE, Embase, CINAHL and trials registries in August 2023. We included randomised controlled trials (RCTs) in children aged 17 years and younger, treated for acute postoperative or postprocedural pain, that compared ibuprofen to placebo or any active comparator. We included RCTs that compared different administration routes, doses of ibuprofen and schedules. We adhered to standard Cochrane methods for data collection and analysis. Our primary outcomes were pain relief reported by the child, pain intensity reported by the child, adverse events, and serious adverse events. We present results using risk ratios (RR) and standardised mean differences (SMD), with the associated confidence intervals (CI). We used GRADE to assess the certainty of the evidence. We included 43 RCTs that enroled 4265 children (3935 children included in this review). We rated the overall risk of bias at the study level as high or unclear for 37 studies that had one or several unclear or high risk of bias judgements across the domains. We judged six studies as having a low risk of bias across all domains. Ibuprofen versus placebo (35 RCTs) No studies reported pain relief reported by the child or a third party, or serious adverse events. Ibuprofen probably reduces child‐reported pain intensity less than two hours postintervention compared to placebo (SMD −1.12, 95% CI −1.39 to −0.86; 3 studies, 259 children; moderate‐certainty evidence). Ibuprofen may reduce child‐reported pain intensity, two hours to less than 24 hours postintervention (SMD −1.01, 95% CI −1.24 to −0.78; 5 studies, 345 children; low‐certainty evidence). Ibuprofen may result in little to no difference in adverse events compared to placebo (RR 0.79, 95% CI 0.51 to 1.23; 5 studies, 384 children; low‐certainty evidence). Ibuprofen versus paracetamol (21 RCTs) No studies reported pain relief reported by the child or a third party, or serious adverse events. Ibuprofen likely reduces child‐reported pain intensity less than two hours postintervention compared to paracetamol (SMD −0.42, 95% CI −0.82 to −0.02; 2 studies, 100 children; moderate‐certainty evidence). Ibuprofen may slightly reduce child‐reported pain intensity two hours to 24 hours postintervention (SMD −0.21, 95% CI −0.40 to −0.02; 6 studies, 422 children; low‐certainty evidence). Ibuprofen may result in little to no difference in adverse events (0 events in each group; 1 study, 44 children; low‐certainty evidence). Ibuprofen versus morphine (1 RCT) No studies reported pain relief or pain intensity reported by the child or a third party, or serious adverse events. Ibuprofen likely results in a reduction in adverse events compared to morphine (RR 0.58, 95% CI 0.40 to 0.83; risk difference (RD) −0.25, 95% CI −0.40 to −0.09; number needed to treat for an additional beneficial outcome (NNTB) 4; 1 study, 154 children; moderate‐certainty evidence). Ibuprofen versus ketorolac (1 RCT) No studies reported pain relief or pain intensity reported by the child, or serious adverse events. Ibuprofen may result in a reduction in adverse events compared to ketorolac (RR 0.51, 95% CI 0.27 to 0.96; RD −0.29, 95% CI −0.53 to −0.04; NNTB 4; 1 study, 59 children; low‐certainty evidence). Despite identifying 43 RCTs, we remain uncertain about the effect of ibuprofen compared to placebo or active comparators for some critical outcomes and in the comparisons between different doses, schedules and routes for ibuprofen administration. This is largely due to poor reporting on important outcomes such as serious adverse events, and poor study conduct or reporting that reduced our confidence in the results, along with small underpowered studies. Compared to placebo, ibuprofen likely results in pain reduction less than two hours postintervention, however, the efficacy might be lower at two hours to 24 hours. Compared to paracetamol, ibuprofen likely results in pain reduction up to 24 hours postintervention. We could not explore if there was a different effect in different kinds of surgeries or procedures. Ibuprofen likely results in a reduction in adverse events compared to morphine, and in little to no difference in bleeding when compared to paracetamol. We remain -Abstract Truncated-
medicine, general & internal